Research is an integral part of what makes The Ohio State University Wexner Medical Center such a force in the global medical community. Our investment in research and commitment to the investigative process has led to many breakthroughs and innovative discoveries. We encourage research at all levels, knowing that it can fuel life-changing results now and in the future. Research also keeps our teams engaged and always learning.

At The Center for Parkinson's Disease and Other Movement Disorders, a robust research program and active clinical trials give patients with Parkinson’s disease (PD) the opportunity to try treatments that may be limited to a few locations or not even available elsewhere. Given the chronic nature of PD and the varied symptoms faced by each patient, this can be a gamechanger.

Research options at Ohio State

Many people wonder about the difference between research and clinical trials. Types of research can vary tremendously, and clinical trials are simply a kind of research. However, research can also include work in the lab or even surveys of patients to collect health history and unique experiences so we can improve how we prevent, diagnose and treat diseases.

A parkinson's disease doctor examines a patient at The Ohio State University Wexner Medical Center.If you’re involved in a clinical trial for PD, you might be among a select group of people offered a new medicine, therapy, medical device or other quality-of-life advantage. It’s important to know that nothing is offered in a clinical trial until it has already been thoroughly studied and tested for safety and effectiveness.

Participation in clinical trials is completely voluntary, and you may withdraw at any time. Your care team can discuss PD trials that are currently recruiting patients, explain the risks and benefits and help you explore your eligibility, as most trials have a list of requirements based on age, gender, symptoms or other factors.

Participate in PD research

The Center for Parkinson's Disease and Other Movement Disorders is involved in ongoing clinical trials, observational studies and nonpharmacological treatment trials. If you’re interested in participating in our research, please contact us at pdresearch@osumc.edu or ask a member of your care team for more information.

If you’d like to explore a list of current clinical studies at Ohio State Wexner Medical Center, visit studysearch.osumc.edu. Under “Find a Study,” use Parkinsons as the keyword for your search.

Participate in PD GENEration study to map the future of PD

PD GENEration is a nationwide initiative sponsored by the Parkinson’s Foundation to offer free genetic testing and genetic counseling for individuals with Parkinson’s disease. By participating, you’ll be contributing your genetic information for researchers to better understand the potential genetic causes of PD, opening the door for better and more effective treatment options.

Additionally, certain genetic variants – detected via these tests – may make you eligible for certain clinical trials.

How long does it take to get results?

After some initial background information and medical history questions, participants will come to Ohio State for an in-person visit to consent to the study, have their blood drawn for genetic testing, and pre-testing genetic counseling. After about 3 to 5 weeks, our genetic counselor will disclose your genetic testing results. You’ll learn about the potential role your gene(s) played in your diagnosis of Parkinson’s and the potential risk of PD for others in your family.

How do you sign up for GENEration study?

To participate, email a member of our neuro genetics team at Ohio State at 614-688-6419 or email us to get more info about GENEration study.

Participate in the Topaz study at no cost, without ever leaving your home 

People with Parkinson’s disease (PD) and parkinsonism have a higher risk of bone fracture, especially hip fractures. The Ohio State University Wexner Medical Center is participating in the Topaz study, which will test if an FDA-approved medicine called zoledronic acid can prevent bone fractures in people living with PD and parkinsonism. The goal of the study is to help those with PD or parkinsonism avoid bone fractures, which can restrict your mobility for a long period of time and impact your quality of life.  

Experts in bone health and PD are leading this study, which is endorsed by the Parkinson’s Foundation and the Parkinson Study Group and is being funded by the National Institute on Aging. Since zoledronic acid is not specifically approved by the FDA for treatment in PD or parkinsonism, this is an investigational research study.  

How can you participate in the Topaz study?  

You may be eligible to join the study if you have PD or parkinsonism, are 60 years or older and haven’t suffered a previous hip fracture.  

If you’re eligible, a nurse will come to your home to give you a short health exam, and you’ll receive a one-time dose of the study treatment (either zoledronic acid or placebo). During the study, participants will be contacted every four months to assess if they’ve had any new fractures. The length of the study contact will be five years.  

To learn more about participating in the Topaz trial, please contact a member of our team at pdresearch@osumc.edu or call 614-688-6685. You can also visit the topazstudy.org.

Learn more about Parkinson's disease

Meet our specialists

Ariane Park, MD, MPH

Ariane Park, MD, MPH

Co-director of The Center for Parkinson's Disease and Other Movement Disorders

Dr. Park manages care for patients with all types of movement disorders, including Parkinson’s disease, tremor and dystonia.

Clinical profile

Mazzoni_Pietro_724x840

Pietro Mazzoni, MD

Neurologist

Jordan_Zach_724x840

Zachary Jordan, MD

Neurologist

Brian Dalm, MD

Brian Dalm, MD

Dr. Dalm is a neurosurgeon specializing in pain and functional neurosurgical disorders. His work includes research into the benefits of neuromodulation therapy for a patient.

 Clinical profile

Clarisse Goas, MS, CNP

Clarisse Goas, MS, CNP

Goas specializes in movement disorders and has experience in clinical trials, including new medication symptomatic interventions, deep brain stimulation and intestinal pump drug delivery systems.

Clinical profile

DavisRozena

Rozena Davis, MS, CNP

Davis is part of the clinical trials team and has experience with advanced therapies, such as deep brain stimulation for a variety of movement disorders, including Parkinson’s disease, dystonia and tremor disorders.

Clinical profile

Jessica Truelove, MS, CNP

Jessica Truelove, MS, CNP

Truelove has specialized training in both cognitive disorders and movement disorders and is part of the research team in both neurology divisions.

Clinical profile

Katherine Ambrogi, BSN, RN

Katherine Ambrogi, BSN, RN

Ambrogi serves as the clinical research manager movement disorders, specifically Parkinson's disease and other tremor disorders. In coordination with the Center for Clinical Research Management, she coordinates, plans, develops and implements clinical protocols in accordance with research parameters set by the principle investigator.

Victoria Miller

Victoria Miller

Clinical Research Coordinator

Jonathan Zins

Jonathan Zins, DPT, PT

Dr. Zins is the Parkinson’s disease team coordinator in outpatient rehabilitation. He is a board-certified neurologic clinical specialist, treating patients with a variety of neurologic injury and disease.

Academic profile

Grim_Sarah_724x840

Sarah Grim, LISW

Grim, as a social worker, provides support for our patients and their caregivers. She shares information on community resources, long-term care and home health, Medicare and Medicaid, work-related issues and more.

klee_victoria_724x840

Victoria Klee, LGC

As a genetic counselor, Klee helps patients understand their family medical history, identify the best genetic test for their movement disorder and help explain their treatment options, including gene-targeting therapies. Klee manages our Parkinson's disease GENEration study.

Subscribe. Get just the right amount of health and wellness in your inbox.